Total number of voting rights and capital on January 31, 2024
|
January 31, 2024 |
Referring to company announcement 02, on January 29, 2024, where Novozymes A/S (“Novozymes”) announced the completion and final registration with the Danish Business Authority of the statutory merger between Novozymes and Chr. Hansen Holding A/S, the share capital has been increased by nominally DKK 374,597,292 from DKK 562,000,000 to DKK 936,597,292 through the issuance of a total of 187,298,646 new Novozymes B-shares in the denomination of DKK 2 each.
Following the above, and pursuant to Article 32 of the Danish Capital Markets Act, it is hereby announced that the total share capital as of today consists of nominally DKK 936,597,292 comprising a total of 468,298,646 shares, divided into 53,743,600 A shares and 414,555,046 B shares with a nominal value of DKK 2 each and a total of 1,903,982,092 voting rights.
| Nominal Value, DKK | Number of shares | |
| A shares | 107,487,200 | 53,743,600 |
| B shares | 829,110,092 | 414,555,046 |
| Total | 936,597,292 | 468,298,646 |
| Contact information | ||
| Investor Relations | ||
| Tobias Bjorklund | +45 3077 8682 | tobb@novonesis.com |
| Anders Enevoldsen | +45 5350 1453 | adev@novonesis.com |
|
Media Relations |
||
| Lina Danstrup | +45 3077 0552 | lind@novonesis.com |
Attachment
WASHINGTON, Dec. 26, 2025 /PRNewswire/ -- Over the past decade, China has evolved from a biotechnology…
SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a…
While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn…
DALLAS, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and…
This Christmas season, President Trump's executive action to advance rescheduling and medical research has finally…
KANAZAWA, Japan, Dec. 26, 2025 /PRNewswire/ -- Scientists at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa…